Specialty Pharma Journal Specialty, Precision & Technology
WHIPPANY, N.J., Feb. 15, 2019 /PRNewswire/ — Bayer has exercised its option, under a change-in-control clause in the …
Read More »Bayer Acquires Full Rights to Loxo Oncology’s Vitrakvi and LOXO-195
Recent Posts
FDA Grants Priority Review to Merck’s sBLA for Keytruda Plus Inlyta as First-Line Treatment for Advanced Renal Cell Carcinoma
KENILWORTH, N.J.–(BUSINESS WIRE)–Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced …
Read More »FDA Announces Breakthrough Therapy Designation to CymaBay’s Seladelpar for Treatment of Primary Biliary Cholangitis
NEWARK, Calif., Feb. 15, 2019 (GLOBE NEWSWIRE) — CymaBay Therapeutics, Inc. (NASDAQ: CBAY), today announced …
Read More »Bayer’s Investigational Darolutamide Plus ADT Significantly Extends Metastasis-Free Survival in Phase 3 Study of Non-Metastatic Castration-Resistant Prostate Cancer
WHIPPANY, N.J., Feb. 14, 2019 /PRNewswire/ — Results from the pivotal Phase III ARAMIS trial in patients with …
Read More »Opdivo Plus Yervoy Shows Response in Pre-Treated Patients with Metastatic Castration-Resistant Prostate Cancer
PRINCETON, N.J.–(BUSINESS WIRE)–Bristol-Myers Squibb Company (NYSE: BMY) today announced data evaluating Opdivo(nivolumab) in combination with Yervoy (ipilimumab) in patients …
Read More »Novartis Enters 10-Target Antibody Discovery Deal with AbCellera
VANCOUVER, British Columbia–(BUSINESS WIRE)–AbCellera, a technology leader in therapeutic antibody discovery from natural immune repertoires, …
Read More »Sarepta Announces FDA Acceptance of Golodirsen NDA for Patients with Duchenne Muscular Dystrophy Amenable to Skipping Exon 53
CAMBRIDGE, Mass., Feb. 14, 2019 (GLOBE NEWSWIRE) — Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in …
Read More »Janssen Announces Preliminary Results from Phase 2 Study in Adults with Metastatic Castration-Resistant Prostate Cancer and DNA-Repair Pathway Defects
SAN FRANCISCO, Feb. 14, 2019 /PRNewswire/ — The Janssen Pharmaceutical Companies of Johnson & Johnson …
Read More »Ultragenyx and Kyowa Kirin Announce Positive Results for Crysvita from Phase 3 Study in Children with X-linked Hypophosphatemia
NOVATO, Calif., TOKYO and LONDON, Feb. 14, 2019 (GLOBE NEWSWIRE) — Ultragenyx Pharmaceutical Inc. (NASDAQ: …
Read More »Merck Increases Focus on Advanced Prostate Cancer, Expanding Immuno-Oncology Program with Three New Phase 3 Trials
KENILWORTH, N.J.–(BUSINESS WIRE)–Merck (NYSE: MRK), known as MSD outside the United States and Canada, today …
Read More »FDA Approves Novartis’ Egaten for the Treatment of Fascioliasis, a Neglected Tropical Disease
Basel, Switzerland, February 13, 2019 – Novartis announced today that the US Food and Drug Administration (FDA) …
Read More »Amgen Enters Multi-Target Collaboration with Abilita Bio for its Membrane Protein Technology
SAN DIEGO, Feb. 13, 2019 /PRNewswire/ — Abilita Bio, Inc. announced today that it has …
Read More »Johnson & Johnson to Acquire Robotic Surgery Company Auris Health for $3.4 Billion
New Brunswick, NJ – February 13, 2019 – Focused on creating the next frontier of surgery, Johnson …
Read More »Boehringer Ingelheim and IBM Collaborate to Explore Use of Blockchain Technology in Clinical Trials
BURLINGTON, Ontario and MARKHAM, Ontario, Feb. 12, 2019 /PRNewswire/ — Boehringer Ingelheim (Canada) Ltd. and …
Read More »Gilead’s Selonsertib Fails to Meet Primary Endpoint in Phase 3 NASH Study
FOSTER CITY, Calif.–(BUSINESS WIRE)–Gilead Sciences, Inc. (Nasdaq: GILD) today announced that STELLAR-4, a Phase 3, …
Read More »